Table 1: DAAs for hepatitis C [9,10,16,24,25,42,48].
| DAA | Class | Approval | Genotype | Barrier to resistance | Potency | Combination (SVR) |
| Boceprevir | NS3/4A PI | 2011 | 1 | Medium | High | RBV + IFN (SVR 61-75%) |
| Telaprevir | NS3/4A PI | 2011 | 1 | Low | High | RBV + IFN (SVR 69-83%) |
| Simeprevir (SIM) | NS3/4A PI | 2013 | 1, 4 | Low | High | with RBV + IFN (SVR79-86%) or with SOF (SVR 95-97%) |
| Asunaprevir (ASV) | NS3/4A PI | 2013 | 1b | Medium | High | with DCV (SVR 82-90%) |
| Paritaprevir/r (PTV/r) | NS3/4A PI (ritonavir boosted) |
2013 | 1, 4 | Low | High | with OBV + DSV ± RBV (SVR 90-99%) |
| Grazoprevir (GZR) | NS3/4A PI | 2016 | 1, 4 | Low | High | with EBR (SVR 92-99%) |
| Sofosbuvir (SOF) | NS5B | 2013 | Pangenotype | High | High |
with RBV + IFN (SVR 89-90%) or with RBV (SVR 97% in GT2/3; SVR 68-84% in GT1) or with SIM (SVR 95-97%) or with LDV (SVR 97-99%) or with VEL (SVR 95-99%) or with DCV (SVR 95-100%) |
| Dasabuvir (DSV) | NS5B | 2014 | 1 | Low | Low | with OB + PTV/r ± RBV (SVR 90-99%) |
| Ledipasvir (LDV) | NS5A | 2014 | 1, 4, 5 | Low | High | with SOF (SVR 97-99%) |
| Ombitasvir (OBV) | NS5A | 2014 | 1, 4 | Medium | High | with PTV/r plus DSV ± RBV (SVR 90-99%) |
| Daclatasvir (DCV) | NS5A | 2014 | Pangenotype | Low | High | with SOF (SVR 91-100%) |
| Elbasvir (EBR) | NS5A | 2016 | Pangenotype | Medium | High | with GZR (SVR 92-99%) |
| Velpatasvir (VEL) | NS5A | 2016 | Pangenotype | Low | High | with SOF (SVR 97-99%) |
| Voxilaprevir (VOX) | NS3/4A PI | 2017 | Pangenotype | High | High | with SOF+VEL (SVR 97-99%) |
| Glecaprevir (GLE) | NS3/4A PI | 2017 | Pangenotype | High | High | With PIB (SVR 99%) |
| Pibrentasvir (PIB) | NS5A | 2017 | Pangenotype | High | High | With GLE (SVR 99%) |